Alfred Sandrock

16.8k total citations · 4 hit papers
59 papers, 8.3k citations indexed

About

Alfred Sandrock is a scholar working on Pathology and Forensic Medicine, Physiology and Oncology. According to data from OpenAlex, Alfred Sandrock has authored 59 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pathology and Forensic Medicine, 17 papers in Physiology and 16 papers in Oncology. Recurrent topics in Alfred Sandrock's work include Multiple Sclerosis Research Studies (21 papers), Polyomavirus and related diseases (16 papers) and Alzheimer's disease research and treatments (16 papers). Alfred Sandrock is often cited by papers focused on Multiple Sclerosis Research Studies (21 papers), Polyomavirus and related diseases (16 papers) and Alzheimer's disease research and treatments (16 papers). Alfred Sandrock collaborates with scholars based in United States, Switzerland and United Kingdom. Alfred Sandrock's co-authors include Fred Lublin, Michael Panzara, Frances Lynn, David H. Miller, Chris H. Polman, Eva Havrdová, Paul O’Connor, Richard A. Rudick, A Wajgt and J. Theodore Phillips and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Alfred Sandrock

56 papers receiving 8.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

2006 2.4k citations Paul O’Connor, Eva Havrdová et al. New England Journal of Medicine profile →
Intramuscular Interferon Beta-1A Therapy Initiated during a First Demyelinating Event in Multiple Sclerosis

2000 1.1k citations Lawrence Jacobs, Roy W. Beck et al. New England Journal of Medicine profile →
Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis

2006 982 citations Richard A. Rudick, William H. Stuart et al. New England Journal of Medicine profile →
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

2012 878 citations Gary Bloomgren, Sandra Richman et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Alfred Sandrock

Since Specialization

Citations

This map shows the geographic impact of Alfred Sandrock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alfred Sandrock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alfred Sandrock more than expected).

Fields of papers citing papers by Alfred Sandrock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alfred Sandrock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alfred Sandrock. The network helps show where Alfred Sandrock may publish in the future.

Co-authorship network of co-authors of Alfred Sandrock

This figure shows the co-authorship network connecting the top 25 collaborators of Alfred Sandrock. A scholar is included among the top collaborators of Alfred Sandrock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alfred Sandrock. Alfred Sandrock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Results from the long‐term extension of PRIME: A randomized Phase 1b trial of aducanumab 2024 ·Alzheimer s & Dementia ·Tianle Chen, John O’Gorman, Carmen Castrillo‐Viguera, Rajasimhan Rajagovindan, (unknown), Ying Tian, (unknown), Philipp von Rosenstiel, Christian von Hehn, Stephen Salloway, Christoph Höck, Roger M. Nitsch, Samantha Budd Haeberlein, Alfred Sandrock, Priya Singhal	11
2	Alzheimer disease neuropathology in a patient previously treated with aducanumab 2022 ·Acta Neuropathologica ·Edward D. Plowey, Thierry Bussière, Raj Rajagovindan, (unknown), Stefan Hamann, Christian von Hehn, Carmen Castrillo‐Viguera, Alfred Sandrock, Samantha Budd Haeberlein, Christopher H. van Dyck, Anita Hüttner	28
3	COVID-19 in Patients with Multiple Sclerosis: Associations with Disease-Modifying Therapies 2021 ·CNS Drugs ·Anthony T. Reder, Diego Centonze, Maria L. Naylor, (unknown), Rajani Rajbhandari, Arman Altincatal, Michelle Kim, (unknown), (unknown), Eunice Jung, Alfred Sandrock, Karen Smirnakis, (unknown), Carl de Moor	85
4	Serum Neurofilament Light (sNfL) for Disease Prognosis and Treatment Monitoring in Multiple Sclerosis Patients:Towards Implementation into Clinical Care (S26.001) 2019 ·Neurology ·Peter A. Calabresi, Jens Kühle, Douglas L. Arnold, R. Philip Kinkel, Ludwig Kappos, Carol M. Singh, Dipen Sangurdekar, Carl de Moor, (unknown), (unknown), Aaron Deykin, Elizabeth Fisher, Alfred Sandrock, Bernd C. Kieseier, Richard A. Rudick, Tatiana Plavina	0
5	Interim Analyses of Fixed-Dose and Titration Cohorts from PRIME: A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study of Aducanumab (S9.006) 2019 ·Neurology ·Carmen Castrillo‐Viguera, Samantha Budd Haeberlein, Philipp von Rosenstiel, Tianle Chen, John O’Gorman, Raj Rajagovindan, (unknown), Guanfang Wang, Spyros Chalkias, (unknown), (unknown), Christoph Höck, Roger M. Nitsch, Alfred Sandrock	2
6	Aducanumab titration dosing regimen: 24-month analysis from PRIME, a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease (S2.003) 2018 ·Neurology ·Philipp von Rosenstiel, Sarah Gheuens, Tianle Chen, John O’Gorman, Ping Chiao, Guanfang Wang, Christian von Hehn, LeAnne Skordos, Christoph Höck, Roger M. Nitsch, Samantha Budd Haeberlein, Alfred Sandrock	3
7	Aducanumab 36-month data from PRIME: a randomized, double-blind, placebo-controlled Phase 1b study in patients with prodromal or mild Alzheimer’s disease (S2.004) 2018 ·Neurology ·Samantha Budd Haeberlein, Sarah Gheuens, Tianle Chen, John O’Gorman, Philipp von Rosenstiel, Ping Chiao, Guanfang Wang, Christian von Hehn, LeAnne Skordos, Christoph Höck, Roger M. Nitsch, Alfred Sandrock	9
8	Titration dosing of aducanumab: Results of a 12-month interim analysis from a randomized, double-blind, placebo-controlled Phase 1b study (PRIME) in patients with prodromal or mild Alzheimer’s Disease (S7.003) 2017 ·Neurology ·Vissia Viglietta, John O’Gorman, Leslie Williams, Tianle Chen, Ahmed Enayetallah, Ping Chiao, Christoph Höck, Roger M. Nitsch, Samantha Budd Haeberlein, Alfred Sandrock	2
9	Randomized, Double-Blind, Placebo-Controlled Studies to Evaluate Treatment with Aducanumab (BIIB037) in Patients with Early Alzheimer’s Disease: Phase 3 Study Design (S1.003) 2016 ·Neurology ·Vissia Viglietta, John O’Gorman, Leslie Williams, Ying Tian, Alfred Sandrock, Rachelle S. Doody, Stephen Salloway, Frederik Barkhof, Bruno Vellas, Mary Sano, Paul Aisen, Jeffrey Sevigny	9
10	Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy breakdown → 2012 ·New England Journal of Medicine ·Gary Bloomgren, Sandra Richman, Christophe Hotermans, Meena Subramanyam, Susan Goelz, (unknown), Sophia Lee, Tatiana Plavina, James Scanlon, Alfred Sandrock, Carmen Bozic	878
11	Anti‐JC virus antibodies: Implications for PML Risk Stratification 2010 ·Annals of Neurology ·Leonid Gorelik, Michaela Lerner, Sarah A. Bixler, Mary Crossman, Brian Schlain, Kenneth J. Simon, (unknown), Anne E. Cheung, Ling Ling Chen, Melissa Berman, (unknown), (unknown), Ted Yednock, Alfred Sandrock, Susan Goelz, Meena Subramanyam	326
12	Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis 2010 ·Journal of the Neurological Sciences ·Ernst-Wilhelm Radüe, William H. Stuart, Peter A. Calabresi, Christian Confavreux, Steven Galetta, Richard A. Rudick, Fred Lublin, Bianca Weinstock‐Guttman, Daniel Wynn, Elizabeth Fisher, Athina Papadopoulou, Frances Lynn, Michael Panzara, Alfred Sandrock	43
13	LINGO-1 and its role in CNS repair 2008 ·The International Journal of Biochemistry & Cell Biology ·Sha Mi, Alfred Sandrock, Robert H. Miller	78
14	Natalizumab plus Interferon Beta-1a for Relapsing Multiple Sclerosis breakdown → 2006 ·New England Journal of Medicine ·Richard A. Rudick, William H. Stuart, Peter A. Calabresi, Christian Confavreux, Steven Galetta, Ernst-Wilhelm Radüe, Fred Lublin, Bianca Weinstock‐Guttman, Daniel Wynn, Frances Lynn, Michael Panzara, Alfred Sandrock	982
15	Infusion-related hypersensitivity reactions during natalizumab treatment 2006 ·Neurology ·J. Theodore Phillips, Paul O’Connor, Eva Havrdová, Michael Hutchinson, Ludwig Kappos, D. H. Miller, C. H. Polman, Fred Lublin, Gavin Giovannoni, A Wajgt, Frances Lynn, Michael Panzara, Alfred Sandrock	29
16	The blood–brain barrier as target of multiple sclerosis research and therapy 2004 ·Journal of Neuroimmunology ·Ralf Gold, Richard M. Ransohoff, Alfred Sandrock, Peter Rieckmann	2
17	Interferon β‐1a for early multiple sclerosis: CHAMPS trial subgroup analyses 2002 ·Annals of Neurology ·Roy W. Beck, Danielle L. Chandler, Stephen R. Cole, Jack H. Simon, Lawrence Jacobs, R. Philip Kinkel, John B. Selhorst, John Rose, Joanna A. Cooper, George P. Rice, Thomas J. Murray, Alfred Sandrock	98
18	Merosin Promotes Neurite Growth and Schwann Cell Migration in Vitro and Nerve Regeneration in Vivo: Evidence Using an Antibody to Merosin, ARM-1 1994 ·Developmental Biology ·E.S. Anton, Alfred Sandrock, William Diller Matthew	75
19	Analysis of Complex Matrices Functional in Neuronal Process Extension Using Monoclonal Antibodies in vitro and in vivo 1989 ·Developmental Neuroscience ·Rebecca Tuttle, Alfred Sandrock, William Diller Matthew	3
20	Substrate-bound nerve growth factor promotes neurite growth in peripheral nerve 1987 ·Brain Research ·Alfred Sandrock, William Diller Matthew	31

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact